advertisement
On TechRepublic: 19 words you don't want in your resume
Find Articles in:
all
Business
Reference
Technology
News
Sports
Health
Autos
Arts
Home & Garden
advertisement

Content provided in partnership with
Thomson / Gale

Paradigm, Celera enter strategic alliance in Ag-Genomics

BT Catalyst,  Feb, 2002  

Paradigm Genetics Inc. (Nasdaq: PDGM) of Research Triangle Park and Celera Genomics (NYSE: CRA) of Rockville, Md., have formed a strategic alliance in agriculture-genomics. Under the terms of the arrangement, Paradigm will acquire Celera's AgGen plant genomics and genotyping business and become the exclusive marketing partner to provide Celera services to the plant-based agriculture industries.

"This strategic partnership means that Paradigm can now offer the full array of agricultural genomic technologies, from gene sequencing, genotyping, and marker-assisted breeding to gene function discovery, gene expression analysis, phenotypic analysis and biochemical profiling," said John A. Ryals, Ph.D., Paradigm's CEO and president.

Most Popular Articles in Technology
An overview of continuous data protection
Why all those current ratings?
Many countries now have a mobile penetration rate above 100%, report says
The Tata Group's big telecom gamble: VSNL's recent acquisition of Tyco ...
MEASURING BANK BRANCH EFFICIENCY USING DATA ENVELOPMENT ANALYSIS: MANAGERIAL ...
More »
advertisement

Upon closing of Paradigm's acquisition of the AgGen genomics and genotyping business, Paradigm's new business unit will be named ParaGen.

As part of the transaction, Celera will receive 422,459 shares of Paradigm common stock and will share future service revenue with Paradigm. Financial details of the marketing partnership were not disclosed.

"We are pleased to enter this relationship with Paradigm Genetics," said J. Craig Venter, Ph.D., chair of Celera's scientific discovery board. "By working with Paradigm, we should realize value from services for the plant-based agricultural industry, while focusing our internal resources on activities related to Celera's therapeutic discovery and online business."

COPYRIGHT 2002 North Carolina Biotechnology Center
COPYRIGHT 2008 Gale, Cengage Learning